{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T17:15:36Z","timestamp":1772039736066,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81974004"],"award-info":[{"award-number":["81974004"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-025-03657-2","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T14:32:55Z","timestamp":1765463575000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness and safety of orelabrutinib combined with rituximab, temozolomide, methotrexate, and cytarabine in intensive chemotherapy-unfit patients with PCNSL in China"],"prefix":"10.1186","volume":"31","author":[{"given":"Zhigang","family":"Fang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fenfen","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaozhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyan","family":"Ling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiajun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengzhi","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaofeng","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"3657_CR1","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13045-022-01356-7","volume":"15","author":"T Chen","year":"2022","unstructured":"Chen T, Liu Y, Wang Y, Chang Q, Wu J, Wang Z, et al. Evidence-based expert consensus on the management of primary central nervous system lymphoma in China. J Hematol Oncol. 2022;15:136.","journal-title":"J Hematol Oncol"},{"key":"3657_CR2","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/nov189","volume":"17","author":"QT Ostrom","year":"2015","unstructured":"Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008\u20132012. Neuro Oncol. 2015;17:iv1\u201362.","journal-title":"Neuro Oncol"},{"key":"3657_CR3","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1200\/JCO.2017.72.7602","volume":"35","author":"C Grommes","year":"2017","unstructured":"Grommes C, DeAngelis LM. Primary CNS lymphoma. J Clin Oncol. 2017;35:2410\u20138.","journal-title":"J Clin Oncol"},{"key":"3657_CR4","doi-asserted-by":"publisher","first-page":"100213","DOI":"10.1016\/j.esmoop.2021.100213","volume":"6","author":"T Calimeri","year":"2021","unstructured":"Calimeri T, Steffanoni S, Gagliardi F, Chiara A, Ferreri AJM. How we treat primary central nervous system lymphoma. ESMO Open. 2021;6:100213.","journal-title":"ESMO Open"},{"key":"3657_CR5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1200\/OP.23.00294","volume":"20","author":"CR D'Angelo","year":"2024","unstructured":"D\u2019Angelo CR. Diagnostic, pathologic, and therapeutic considerations for primary CNS lymphoma. JCO Oncol Pract. 2024;20:195\u2013202.","journal-title":"JCO Oncol Pract"},{"key":"3657_CR6","doi-asserted-by":"publisher","first-page":"8323","DOI":"10.2147\/OTT.S192379","volume":"13","author":"M Holdhoff","year":"2020","unstructured":"Holdhoff M, Wagner-Johnston N, Roschewski M. Systemic approach to recurrent primary CNS lymphoma: perspective on current and emerging treatment strategies. Onco Targets Ther. 2020;13:8323\u201335.","journal-title":"Onco Targets Ther"},{"key":"3657_CR7","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41375-020-01072-6","volume":"35","author":"T Wen","year":"2021","unstructured":"Wen T, Wang J, Shi Y, Qian H, Liu P. Inhibitors targeting Bruton\u2019s tyrosine kinase in cancers: drug development advances. Leukemia. 2021;35:312\u201332.","journal-title":"Leukemia"},{"key":"3657_CR8","doi-asserted-by":"publisher","first-page":"1034668","DOI":"10.3389\/fonc.2022.1034668","volume":"12","author":"J Shen","year":"2022","unstructured":"Shen J, Liu J. Bruton\u2019s tyrosine kinase inhibitors in the treatment of primary central nervous system lymphoma: a mini-review. Front Oncol. 2022;12:1034668.","journal-title":"Front Oncol"},{"key":"3657_CR9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ejca.2019.05.024","volume":"117","author":"C Soussain","year":"2019","unstructured":"Soussain C, Choquet S, Blonski M, Leclercq D, Houillier C, Rezai K, et al. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: final analysis of the phase II \u201cproof-of-concept\u201d iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network. Eur J Cancer. 2019;117:121\u201330.","journal-title":"Eur J Cancer"},{"key":"3657_CR10","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1182\/blood-2018-09-875732","volume":"133","author":"C Grommes","year":"2019","unstructured":"Grommes C, Tang SS, Wolfe J, Kaley TJ, Daras M, Pentsova EI, et al. Phase 1b trial of an ibrutinib-based combination therapy in recurrent\/refractory CNS lymphoma. Blood. 2019;133:436\u201345.","journal-title":"Blood"},{"key":"3657_CR11","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1080\/10428194.2024.2333985","volume":"65","author":"L Schaff","year":"2024","unstructured":"Schaff L, Nayak L, Grommes C. Bruton\u2019s tyrosine kinase (BTK) inhibitors for the treatment of primary central nervous system lymphoma (PCNSL): current progress and latest advances. Leuk Lymphoma. 2024;65:882\u201394.","journal-title":"Leuk Lymphoma"},{"key":"3657_CR12","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s40265-021-01482-5","volume":"81","author":"S Dhillon","year":"2021","unstructured":"Dhillon S. Orelabrutinib: first approval. Drugs. 2021;81:503\u20137.","journal-title":"Drugs"},{"key":"3657_CR13","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/ajh.26826","volume":"98","author":"W Xu","year":"2023","unstructured":"Xu W, Zhou K, Wang T, Yang S, Liu L, Hu Y, et al. Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma patients: multi-center, single-arm, open-label, phase 2 study. Am J Hematol. 2023;98:571\u20139.","journal-title":"Am J Hematol"},{"key":"3657_CR14","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1002\/ajh.27064","volume":"98","author":"L Deng","year":"2023","unstructured":"Deng L, Li Z, Zhang H, Huang H, Hu J, Liu L, et al. Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: a phase 2, multicenter, open-label study. Am J Hematol. 2023;98:1742\u201350.","journal-title":"Am J Hematol"},{"key":"3657_CR15","doi-asserted-by":"publisher","first-page":"4349","DOI":"10.1182\/bloodadvances.2022009168","volume":"7","author":"LJ Deng","year":"2023","unstructured":"Deng LJ, Zhou KS, Liu LH, Zhang MZ, Li ZM, Ji CY, et al. Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1\/2, open-label, multicenter, single-arm study. Blood Adv. 2023;7:4349\u201357.","journal-title":"Blood Adv"},{"key":"3657_CR16","doi-asserted-by":"publisher","first-page":"e19041","DOI":"10.1200\/JCO.2024.42.16_suppl.e19041","volume":"42","author":"Y Xia","year":"2024","unstructured":"Xia Y, Cai Q, Zhang P, Tian X, Fang X. Orelabrutinib, rituximab, temozolomide and high-dose methotrexate (RMOT) in newly diagnosed primary central nervous system lymphoma (PCNSL): a retrospective analysis on efficacy and safety. J Clin Oncol. 2024;42:e19041.","journal-title":"J Clin Oncol"},{"key":"3657_CR17","doi-asserted-by":"publisher","first-page":"6228","DOI":"10.1182\/blood-2023-186219","volume":"142","author":"L Xing","year":"2023","unstructured":"Xing L, Wei H, Liu D, Wang H, Li P, Xie L, et al. Methotrexate in combination with Orelabrutinib, Thiotepa, and Rituximab (R-MTO) followed by autologous stem-cell transplant for primary central nervous system lymphoma treatment. Blood. 2023;142:6228.","journal-title":"Blood"},{"key":"3657_CR18","doi-asserted-by":"publisher","first-page":"6225","DOI":"10.1182\/blood-2023-181427","volume":"142","author":"Y Yuan","year":"2023","unstructured":"Yuan Y, Wang Q, Zhuang D, Ding T, Chen H, Zhu F, et al. Phase 1 trial of Orelabrutinib in combination with Rituximab, Methotrexate, and Dexamethasone in patients with newly diagnosed primary CNS lymphoma implementing Bayesian design for dose-seeking. Blood. 2023;142:6225.","journal-title":"Blood"},{"key":"3657_CR19","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1182\/blood-2022-165710","volume":"140","author":"S Zhao","year":"2022","unstructured":"Zhao S, Liu Y, Zhu Z, He J, Liu L, Wang X, et al. Orelabrutinib, Rituximab, and high-dose Methotrexate (HD-MTX) in newly diagnosed primary central nervous system lymphoma (PCNSL): a retrospective analysis on efficacy, safety, and biomarker. Blood. 2022;140:1338\u20139.","journal-title":"Blood"},{"key":"3657_CR20","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1182\/blood-2024-198355","volume":"144","author":"L Sheng","year":"2024","unstructured":"Sheng L, Ouyang G, Lai Y, Nie S, Wang D, Tang S, et al. Preliminary data on the efficacy and safety of Orelabrutinib combined with Rituximab and Methotrexate (ORM regimen) as first-line treatment for primary central nervous system lymphoma, and the exploration of cerebrospinal fluid Ctdna dynamic monitoring. Blood. 2024;144:4500.","journal-title":"Blood"},{"key":"3657_CR21","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1200\/JCO.2005.13.524","volume":"23","author":"LE Abrey","year":"2005","unstructured":"Abrey LE, Batchelor TT, Ferreri AJ, Gospodarowicz M, Pulczynski EJ, Zucca E, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23:5034\u201343.","journal-title":"J Clin Oncol"},{"key":"3657_CR22","doi-asserted-by":"publisher","first-page":"534","DOI":"10.3324\/haematol.2014.108472","volume":"100","author":"EJ Pulczynski","year":"2015","unstructured":"Pulczynski EJ, Kuittinen O, Erlanson M, Hagberg H, Foss\u00e5 A, Eriksson M, et al. Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group. Haematologica. 2015;100:534\u201340.","journal-title":"Haematologica"},{"key":"3657_CR23","doi-asserted-by":"publisher","first-page":"3905","DOI":"10.1002\/cncr.34985","volume":"129","author":"O Bairey","year":"2023","unstructured":"Bairey O, Taliansky A, Glik A, Amiel A, Yust-Katz S, Gurion R, et al. A phase 2 study of ibrutinib maintenance following first-line high-dose methotrexate-based chemotherapy for elderly patients with primary central nervous system lymphoma. Cancer. 2023;129:3905\u201314.","journal-title":"Cancer"},{"key":"3657_CR24","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1038\/sj.leu.2402573","volume":"16","author":"M Akutsu","year":"2002","unstructured":"Akutsu M, Furukawa Y, Tsunoda S, Izumi T, Ohmine K, Kano Y. Schedule-dependent synergism and antagonism between methotrexate and cytarabine against human leukemia cell lines in vitro. Leukemia. 2002;16:1808\u201317.","journal-title":"Leukemia"},{"key":"3657_CR25","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1182\/blood.2020008377","volume":"140","author":"LR Schaff","year":"2022","unstructured":"Schaff LR, Grommes C. Primary central nervous system lymphoma. Blood. 2022;140:971\u20139.","journal-title":"Blood"},{"key":"3657_CR26","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1200\/JCO.2012.46.9957","volume":"31","author":"JL Rubenstein","year":"2013","unstructured":"Rubenstein JL, Hsi ED, Johnson JL, Jung SH, Nakashima MO, Grant B, et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol. 2013;31:3061\u20138.","journal-title":"J Clin Oncol"},{"key":"3657_CR27","doi-asserted-by":"publisher","first-page":"8676","DOI":"10.1002\/cam4.3499","volume":"9","author":"F Chen","year":"2020","unstructured":"Chen F, Pang D, Guo H, Ou Q, Wu X, Jiang X, et al. Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy: a real-world experience of off-label ibrutinib use. Cancer Med. 2020;9:8676\u201384.","journal-title":"Cancer Med"},{"key":"3657_CR28","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1182\/blood-2020-138764","volume":"136","author":"L Renaud","year":"2020","unstructured":"Renaud L, Bossard J-B, Terriou L, Cambier N, Chanteau G, Carpentier B, et al. Treatment with temozolomide and ibrutinib in recurrent\/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL). Blood. 2020;136:23\u20134.","journal-title":"Blood"},{"key":"3657_CR29","doi-asserted-by":"publisher","first-page":"ii73","DOI":"10.1093\/neuonc\/noad137.242","volume":"25","author":"H Nagashima","year":"2023","unstructured":"Nagashima H, Tanaka K, Yamanishi S, Sasayama T. P11.08.B R-MPV therapy for primary central nervous system lymphoma; single center retrospective analysis. Neuro-oncology. 2023;25:ii73.","journal-title":"Neuro-oncology"},{"key":"3657_CR30","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41392-024-01941-x","volume":"9","author":"Z Zeng","year":"2024","unstructured":"Zeng Z, Yang A, Yang J, Zhang S, Xing Z, Wang X, et al. Sintilimab (anti-PD-1 antibody) combined with high-dose methotrexate, temozolomide, and rituximab (anti-CD20 antibody) in primary central nervous system lymphoma: a phase 2 study. Signal Transduct Target Ther. 2024;9:229.","journal-title":"Signal Transduct Target Ther"},{"key":"3657_CR31","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/S2352-3026(16)00036-3","volume":"3","author":"AJM Ferreri","year":"2016","unstructured":"Ferreri AJM, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016;3:e217\u201327.","journal-title":"Lancet Haematol"},{"key":"3657_CR32","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1182\/blood-2014-10-604561","volume":"125","author":"A Omuro","year":"2015","unstructured":"Omuro A, Correa DD, DeAngelis LM, Moskowitz CH, Matasar MJ, Kaley TJ, et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood. 2015;125:1403\u201310.","journal-title":"Blood"},{"key":"3657_CR33","doi-asserted-by":"publisher","first-page":"CT132","DOI":"10.1158\/1538-7445.AM2020-CT132","volume":"80","author":"B Zhang","year":"2020","unstructured":"Zhang B, Zhao R, Liang R, Gao Y, Liu R, Chen X, et al. Abstract CT132: Orelabrutinib, a potent and selective Bruton\u2019s tyrosine kinase inhibitor with superior safety profile and excellent PK\/PD properties. Cancer Res. 2020;80:CT132.","journal-title":"Cancer Res"},{"key":"3657_CR34","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1080\/17460441.2023.2236547","volume":"18","author":"P Robak","year":"2023","unstructured":"Robak P, Witkowska M, Wolska-Washer A, Robak T. The preclinical discovery and development of orelabrutinib as a novel treatment option for B-cell lymphoid malignancies. Expert Opin Drug Discov. 2023;18:1065\u201376.","journal-title":"Expert Opin Drug Discov"},{"key":"3657_CR35","first-page":"158","volume":"21","author":"H Yu","year":"2021","unstructured":"Yu H, Wang X, Li J, Ye Y, Wang D, Fang W, et al. Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma. Mol Ther. 2021;21:158\u201370.","journal-title":"Mol Ther"},{"key":"3657_CR36","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1007\/s10072-024-07348-4","volume":"45","author":"XL Guo","year":"2024","unstructured":"Guo XL, Zhao ZY, Guo XF, Zuo YB, Li JA, Nie ZY, et al. Effectiveness and safety of orelabrutinib with rituximab and lenalidomide in low KPS score and elderly patients with newly diagnosed primary central nervous system lymphoma-a single-center retrospective study. Neurol Sci. 2024;45:2931\u20134.","journal-title":"Neurol Sci"},{"key":"3657_CR37","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1111\/bjh.19659","volume":"205","author":"JH Yi","year":"2024","unstructured":"Yi JH, Kim SJ, Yang DH, Do YR, Won JH, Baek D, et al. Combination of rituximab and methotrexate followed by rituximab and cytarabine in elderly patients with primary central nervous system lymphoma. Br J Haematol. 2024;205:1773\u201381.","journal-title":"Br J Haematol"},{"key":"3657_CR38","doi-asserted-by":"publisher","first-page":"4489","DOI":"10.1200\/JCO.2003.04.056","volume":"21","author":"H Pels","year":"2003","unstructured":"Pels H, Schmidt-Wolf IG, Glasmacher A, Schulz H, Engert A, Diehl V, et al. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol. 2003;21:4489\u201395.","journal-title":"J Clin Oncol"},{"key":"3657_CR39","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1093\/annonc\/mdn628","volume":"20","author":"G Illerhaus","year":"2009","unstructured":"Illerhaus G, Marks R, M\u00fcller F, Ihorst G, Feuerhake F, Deckert M, et al. High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study. Ann Oncol. 2009;20:319\u201325.","journal-title":"Ann Oncol"},{"key":"3657_CR40","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1093\/annonc\/mdq712","volume":"22","author":"K Fritsch","year":"2011","unstructured":"Fritsch K, Kasenda B, Hader C, Nikkhah G, Prinz M, Haug V, et al. Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly. Ann Oncol. 2011;22:2080\u20135.","journal-title":"Ann Oncol"},{"key":"3657_CR41","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1182\/blood-2020-140172","volume":"136","author":"Y Song","year":"2020","unstructured":"Song Y, Xu W, Song Y, Liu L, Lin S, Li Z, et al. Pooled analysis of safety data from clinical trials of orelabrutinib monotherapy in hematologic malignancies. Blood. 2020;136:43.","journal-title":"Blood"},{"key":"3657_CR42","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.7150\/jca.85756","volume":"14","author":"Y Li","year":"2023","unstructured":"Li Y, Li Y, Zeng R, He Y, Liang L, Ou L, et al. High-dose methotrexate, thiotepa, orelabrutinib combined with or without rituximab in primary or secondary central nervous system diffuse large B-cell lymphoma: a single-center retrospective analysis. J Cancer. 2023;14:3182\u201390.","journal-title":"J Cancer"},{"key":"3657_CR43","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1007\/s10637-022-01219-5","volume":"40","author":"JJ Wu","year":"2022","unstructured":"Wu JJ, Wang WH, Dong M, Ma SS, Zhang XD, Zhu LN, et al. Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment of central nervous system lymphoma: a retrospective study. Invest New Drugs. 2022;40:650\u20139.","journal-title":"Invest New Drugs"},{"key":"3657_CR44","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s13045-022-01353-w","volume":"15","author":"A Alu","year":"2022","unstructured":"Alu A, Lei H, Han X, Wei Y, Wei X. BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies. J Hematol Oncol. 2022;15:138.","journal-title":"J Hematol Oncol"},{"key":"3657_CR45","doi-asserted-by":"publisher","first-page":"901797","DOI":"10.3389\/fonc.2022.901797","volume":"12","author":"C Yang","year":"2022","unstructured":"Yang C, Cui Y, Ren X, Li M, Yu K, Shen S, et al. Orelabrutinib combined with lenalidomide and immunochemotherapy for relapsed\/refractory primary central nervous system lymphoma: a retrospective analysis of case series. Front Oncol. 2022;12:901797.","journal-title":"Front Oncol"},{"key":"3657_CR46","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1182\/blood.2024024667","volume":"144","author":"JR Brown","year":"2024","unstructured":"Brown JR, Eichhorst B, Lamanna N, O\u2019Brien SM, Tam CS, Qiu L, et al. Sustained benefit of zanubrutinib vs ibrutinib in patients with R\/R CLL\/SLL: final comparative analysis of ALPINE. Blood. 2024;144:2706\u201317.","journal-title":"Blood"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03657-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-03657-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03657-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T12:05:25Z","timestamp":1768392325000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40001-025-03657-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3657"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-03657-2","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]},"assertion":[{"value":"20 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the Medical Ethics Committee of the Third Affiliated Hospital, Sun Yat-sen University (Ethical Approval Number: II2023-287-01) and was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice Guidelines. Written informed consent was obtained from each patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"77"}}